Table 2 Distribution of predictive factors in relation to subgroups and in relation to treatment, with corresponding rates for pCR
ddAT – Tamoxifen (n = 98) | ddAT + Tamoxifen (n = 98) | |||||
|---|---|---|---|---|---|---|
n | % | pCR (%) | n | % | pCR (%) | |
Menopausal status: | ||||||
Premenopausal | 50 | 51.0 | 10.0 | 56 | 57.1 | 12.5 |
Peri-/postmenopausal | 48 | 49.0 | 8.3 | 42 | 42.9 | 2.4 |
Tumour size: | ||||||
≤ 4 cm | 58 | 59.2 | 12.1 | 56 | 57.1 | 8.9 |
> 4 cm | 40 | 40.8 | 5.0 | 42 | 42.9 | 7.1 |
Clinical nodal status: | ||||||
Negative | 52 | 53.1 | 15.4 | 46 | 46.9 | 13.0 |
Positive | 46 | 46.9 | 2.2 | 52 | 53.1 | 3.9 |
Grade: | ||||||
I/II | 46 | 47.9 | 4.3 | 44 | 44.9 | 0 |
III | 50 | 52.1 | 14.0 | 54 | 55.1 | 14.8 |
Clinical response after two cycles: | ||||||
cPR/cCR | 45 | 48.9 | 13.3 | 50 | 54.3 | 12.0 |
cNC/cPD | 47 | 51.1 | 4.3 | 42 | 45.7 | 4.8 |
ER: | ||||||
0 to 9% | 40 | 40.8 | 17.5 | 46 | 46.9 | 17.4 |
10 to 100% | 58 | 59.2 | 3.5 | 52 | 53.1 | 0 |
PgR: | ||||||
0 to 9% | 55 | 56.1 | 14.5 | 64 | 65.3 | 12.5 |
10 to 100% | 43 | 43.9 | 2.3 | 34 | 34.7 | 0 |
Ki-67: | ||||||
0 to 15% | 42 | 42.9 | 2.4 | 33 | 33.7 | 6.1 |
16 to 30% | 21 | 21.4 | 0 | 22 | 22.5 | 4.5 |
31 to 100% | 35 | 35.7 | 22.9 | 43 | 43.9 | 11.6 |
HER2: | ||||||
0 to 2+ | 73 | 76.0 | 9.6 | 75 | 76.5 | 10.7 |
3+ | 23 | 24.0 | 8.7 | 23 | 23.5 | 0 |
p53: | ||||||
1 to 50% | 47 | 48.0 | 6.4 | 44 | 44.9 | 4.5 |
0 + 51 to 100% | 51 | 52.0 | 11.8 | 54 | 55.1 | 11.1 |
bcl-2: | ||||||
0 to 1+ | 60 | 61.2 | 13.3 | 64 | 65.3 | 12.5 |
2 to 3+ | 38 | 38.8 | 2.6 | 34 | 34.7 | 0 |